查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456981

體外受精 (IVF) 全球市場 - 2024 年至 2029 年預測

Global In Vitro Fertilization (IVF) Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

體外受精 (IVF) 市場預計在預測期內將以 9.37% 的複合年成長率成長，到 2029 年市場規模將從 2022 年的 245.2 億美元達到 458.95 億美元。

一系列被稱為體外受精 (IVF) 的先進技術用於治療遺傳或生殖問題並幫助懷孕。輸卵管阻塞或受損的患者、男性因素不孕症、女性排卵障礙、卵巢早衰、子宮肌瘤、輸卵管切除和不明原因不孕症是可以透過體外受精治療的一些不孕症。這一成長是由於生活方式的改變導致男性和女性不孕症的增加。社會對不孕症治療的理解和接受的開拓預計將促進體外受精（IVF）方法的使用並加速體外受精（IVF）市場的發展。

然而，限制體外受精（IVF）潛在市場的一個主要因素是治療成本，這是全世界眾所周知的。

市場促進因素：

  • 初為人母的中位年齡的增加預計將推動市場成長。

人口擴張顯著增加了初為人母的中位年齡，因為越來越多的女性選擇職業而不是計劃生育和晚婚。避孕藥具的有效使用也顯著影響首次母親的中位年齡，預計將大大有助於體外受精（IVF）市場的擴張。

  • 精子分離系統領域預計將推動市場成長

精子分離系統在體外受精 (IVF) 和人工授精等輔助生殖技術 (ART) 中至關重要，可為後續治療提供精製的樣本。市場成長是由不孕症診所和婦科醫生開發用於 ART 手術的新設備的公司推動的。擴大使用精子注射器等先進技術來分選高品質精子，預計將推動該領域的成長。

按最終用戶

IVF 市場根據身體區域分為生育診所、醫院和研究中心。臨床研究中心預計將成長最快，因為它們承擔了不孕症問題及其可能治療方法的大部分研究。

按地區

按地區分類，體外受精市場分為北美、南美、歐洲、中東和非洲以及亞太地區。亞太地區的市場佔有率最高。亞太地區人口眾多，IVF意識不斷增強，IVF治療費用低廉，不孕症人群不斷增加。

主要進展

  • 2023 年 5 月 - AIVF 和 Genea Biomedx 宣布推出旨在徹底改變 IVF 市場的整合系統。該系統結合了 Genea Biomedx 的 Geri 延時培養箱和 AIVF 的 EMA AI 平台，以低成本記錄個人化 IVF 護理。該系統增加了診所收益，同時透過提高效率和改善患者就診降低了患者成本。 AIVF 的 Geri 延時培養箱與 Genea Biomedx 的先進 EM AI 平台相結合，為個人化和最佳化的 IVF 護理提供了廣泛的機會。
  • 2022 年 6 月 - 全球細胞培養基和輔助生殖技術領導者 FUJIFILM Irvine Scientific 獲得了人工智慧 (AI) 相關智慧財產權的獨家許可。由麻省總醫院和布萊根婦女醫院的研究人員共同開發並獲得專利。 FUJIFILM Irvine Scientific 計劃向公司提供該技術的非獨家許可，並正在全球範圍內尋求合約。這種基於影像的解決方案可以輕鬆整合到當前的 IVF業務中，無需資本支出，為測試設施將人工智慧和影像分析整合到其工作流程中提供了一個更簡單、更實惠的切入點。

提供的產品

  • 連續單一培養物-NX Complete (CSCM-NXC) 是一種低乳酸、單步培養物，已在治療環境中證明可促進胚囊發育。 CSCM-NXC 適用於受精和胚胎培養長達 5 天和 6 天。此培養基設計用於連續培養系統，無需更換培養皿或培養基。它消除不必要的壓力並有助於保持有效的新陳代謝率。您可以選擇預先添加 HSA 的蛋白，使最終的總蛋白濃度為 5 mg/mL。
  • FreyGen ALF：FreyGen ALF 是 IVFtech ApS 的培養箱系列，經過廣泛的研究，提供了根據醫生要求量身設計理想的「易於管理和最佳結果」培養箱所需的知識。 Freigen的培養箱系列可以讓卵子和胚胎在理想的環境中發育和培養。桌上型培養箱也稱為乾式培養箱，用於培養箱。托盤也是可拆卸的，非常容易清洗，您甚至可以將盤子放在電爐上並將它們運送到您的工作空間。配備資料記錄器和遠端警報系統，醫生可以了解培養箱的性能。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球體外受精 (IVF) 市場：依週期類型

  • 介紹
  • 新的
  • 解凍
  • 捐贈卵子

第6章 體外受精 (IVF) 全球市場：依最終使用者分類

  • 介紹
  • 不孕不育診所
  • 醫院和研究中心

第7章 體外受精（IVF）全球市場：依地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Cooper Surgical
  • Vitrolife AB
  • Thermo Fisher Scientific Inc.
  • Cook Medicals
  • FUJIFILM Irvine Scientific
  • Nikon Instruments Inc.
  • Merck KGaA
  • Genea Limited
  • IVFtech ApS
  • Hamilton Thorne, Inc.
簡介目錄
Product Code: KSI061611468

The in vitro fertilization (IVF) market is anticipated to expand at a CAGR of 9.37% over the forecast period, from US$24.52 billion in 2022 to a total market value of US$45.895 billion by 2029.

A sophisticated set of techniques known as in vitro fertilization (IVF) is used to cure genetic or reproductive issues and aid in child conception. Patients with blocked or damaged fallopian tubes, male factor infertility, women with ovulation disorders, premature ovarian failure, uterine fibroids, excised fallopian tubes, and unexplained infertility are among the infertility conditions that can be treated with IVF. The increase may be attributable to the increased rates of male and female infertility brought on by lifestyle changes. Growing public understanding and acceptance of infertility treatment will encourage the use of in vitro fertilization (IVF) methods, which will accelerate the development of the in vitro fertilization (IVF) market.

However, the main factor limiting the potential market for in vitro fertilization (IVF) is the cost of the treatments, which is well-known around the world.

MARKET DRIVERS:

  • The increasing number of median age of first-time mothers is anticipated to drive the market growth

Because more women are choosing careers over family planning and later marriages than in the past, the median age of first-time mothers has increased significantly as a result of the expanding human population. The effective use of contraceptives has also significantly influenced the median age of first-time mothers, and this is anticipated to significantly fuel the expansion of the in vitro fertilization (IVF) market.

  • The segment of sperm separation systems is expected to surge the growth of the market

Sperm separation systems are crucial in assisted reproductive technologies (ART) like in vitro fertilization (IVF) and artificial insemination, providing purified samples for subsequent procedures. The market growth is driven by companies developing novel devices for ART procedures in fertility clinics and obstetrician-gynaecologist practices. The increasing use of advanced technology, such as sperm syringes, in selecting high-quality sperm is expected to fuel the segment growth.

By End-User

By body part, the In-Vitro Fertilization Market is segmented as Fertility Clinics Hospitals & Research Centers. The Clinical research centers are anticipated to have the fastest growth owing to the majority of research on fertility problems and their possible treatment.

By Geography

Geographically, the In-Vitro Fertilization Market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The greatest market share corresponds to the Asia-Pacific region, which has a huge population base, rising IVF treatment awareness, low IVF treatment prices, and an increase in the population of infertile people.

Key Developments:

  • May 2023- AIVF and Genea Biomedx have announced the launch of an integrated system aimed at revolutionizing the IVF market. The system combines Genea Biomedx's Geri time-lapse incubator with AIVF's EMA AI platform, offering personalized IVF care at a reduced cost. This system will reduce patient costs while increasing clinic revenues as efficiency increases and patient access improves. The combination of AIVF's Geri time-lapse incubator and Genea Biomedx's advanced EM AI platform will provide widespread access to personalized, optimized IVF care.
  • June 2022- FUJIFILM Irvine Scientific, a global leader in cell culture media and assisted reproductive technologies, has obtained an exclusive license to intellectual property related to artificial intelligence (AI). Researchers from Massachusetts General Hospital and Brigham and Women's Hospital collaborated to develop and patent the method. FUJIFILM Irvine Scientific plans to offer a non-exclusive license of the technology to businesses, seeking agreements globally. The image-based solution integrates easily into current IVF operations without capital expenditure, offering laboratories a simpler and more affordable entry point for integrating AI and image analysis into their workflows.

Product Offerings:

  • Continuous Single Culture-NX Complete: Continuous Single Culture-NX Complete (CSCM-NXC) is a low-lactate, single-step culture medium with a track record in the therapeutic setting for enhancing blastocyst development. The CSCM-NXC is intended for fertilization and embryo culture up to days 5 and 6. This medium is designed to be utilized in an ongoing culture system without dish replacement or medium replacement. Removing unneeded stress, it supports the maintenance of efficient metabolic rates. Pre-supplemented with HSA, with a final total protein concentration of 5 mg/mL, is the available option.
  • FreyGen ALF: FreyGen ALF is a line of incubators by IVFtech ApS built on an extensive study that provided the knowledge required to design the ideal "simple to manage - best results" incubators tailored to physicians' requirements. Oocytes and embryos can be developed and incubated in the ideal environment with the help of the FreyGen line of incubators. Benchtop incubators also referred to as dry incubators, are what are used in incubators. The fact that the trays are also removable makes it so much simpler to clean them and carry dishes to a workspace on a warm plate. It contains a data logger and a remote alert system so the physician can keep track of the incubator's performance.

Segmentation

By Cycle Type

  • Fresh IVF Cycle
  • Thawed IVF Cycle
  • Donor Egg IVF Cycles

By End-User

  • Fertility Clinics
  • Hospitals and research centers

By Geography

  • North America
  • USA
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET, BY CYCLE TYPE

  • 5.1. Introduction
  • 5.2. Fresh IVF Cycle
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Thawed IVF Cycle
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Donor Egg IVF Cycles
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET, BY END-USER

  • 6.1. Introduction
  • 6.2. Fertility clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Hospitals and research centers
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Cycle Type
    • 7.2.2. By End-Users
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Cycle Type
    • 7.3.2. By End-Users
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Cycle Type
    • 7.4.2. By End-Users
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Cycle Type
    • 7.5.2. By End-Users
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Cycle Type
    • 7.6.2. By End-Users
    • 7.6.3. By Country
      • 7.6.3.1. Japan
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. China
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Cooper Surgical
  • 9.2. Vitrolife AB
  • 9.3. Thermo Fisher Scientific Inc.
  • 9.4. Cook Medicals
  • 9.5. FUJIFILM Irvine Scientific
  • 9.6. Nikon Instruments Inc.
  • 9.7. Merck KGaA
  • 9.8. Genea Limited
  • 9.9. IVFtech ApS
  • 9.10. Hamilton Thorne, Inc.